NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PHGE

BiomX Inc

Jul 09 • 04:00PM ET

0.4200

Dollar change -0.0100
Percentage change -2.33	%

Healthcare • Biotechnology • Israel • AMEX

Peers: CRSP EDIT NTLA BEAM ADPT SGMO FDMT BLUE SPRO PSTX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.51	Insider Own	48.11%	Shs Outstand	24.97M	Perf Week	-7.71%
Market Cap	11.00M	Forward P/E	-	EPS next Y	-1.44	Insider Trans	0.00%	Shs Float	13.58M	Perf Month	-10.47%
Enterprise Value	17.86M	PEG	-	EPS next Q	-0.26	Inst Own	34.45%	Short Float	1.74%	Perf Quarter	-29.41%
Income	-16.15M	P/S	-	EPS this Y	61.16%	Inst Trans	-8.30%	Short Ratio	1.56	Perf Half Y	-45.77%
Sales	0.00M	P/B	1.79	EPS next Y	-10.34%	ROA	-25.38%	Short Interest	0.24M	Perf YTD	-42.47%
Book/sh	0.23	P/C	0.52	EPS next 5Y	22.65%	ROE	-68.18%	52W High	3.86 -89.13%	Perf Year	-87.88%
Cash/sh	0.80	P/FCF	-	EPS past 3/5Y	52.69% 47.40%	ROIC	-49.46%	52W Low	0.34 23.53%	Perf 3Y	-94.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.46% 10.21%	Perf 5Y	-99.24%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	89.52%	Oper. Margin	-	ATR (14)	0.04	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.35	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	39.47	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.35	EPS Q/Q	88.08%	SMA20	-5.54%	Beta	1.44	Target Price	15.50
Payout	-	Debt/Eq	0.38	Sales Q/Q	-	SMA50	-16.04%	Rel Volume	1.66	Prev Close	0.43
Employees	57	LT Debt/Eq	0.33	Earnings	May 15 BMO	SMA200	-38.12%	Avg Volume	151.47K	Price	0.42
IPO	Mar 13, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	8.33% -	Trades		Volume	251,607	Change	-2.33%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-21	Initiated	Ladenburg Thalmann	Buy	$25

Jul-08-25 08:30AM	BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis (GlobeNewswire)
May-19-25 10:02AM	BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference (GlobeNewswire)
May-16-25 03:13AM	BiomX Inc (PHGE) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience (GuruFocus.com)
May-15-25 06:30AM	BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates (GlobeNewswire)
May-08-25 07:00AM	BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025 (GlobeNewswire)
09:55AM	Loading…
Apr-18-25 09:55AM	BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Apr-01-25 06:30AM	BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure (GlobeNewswire) -11.28%
Mar-31-25 06:30AM	BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) (GlobeNewswire)
Mar-25-25 06:30AM	BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates (GlobeNewswire) -7.17%
Mar-19-25 12:35PM	BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 (GlobeNewswire)
Feb-26-25 08:00AM	BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million (GlobeNewswire) -14.03%
Dec-16-24 08:00AM	BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards (GlobeNewswire)
Nov-14-24 06:30AM	BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates (GlobeNewswire)
Nov-12-24 12:20PM	BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024 (GlobeNewswire)
Oct-16-24 07:05AM	BiomX announces mandatory unit separation (TipRanks)
07:00AM	Loading…
Oct-15-24 07:00AM	BiomX Announces a Mandatory Unit Separation (GlobeNewswire)
Sep-18-24 08:00AM	BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference (GlobeNewswire)
Sep-04-24 08:00AM	BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Sep-03-24 08:00AM	BiomX to Present Positive Phase 1b/2a Clinical Trial Data for BX004 at the European Respiratory Society (ERS) Congress 2024 (GlobeNewswire) -7.38%
Aug-16-24 10:55AM	UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split (GlobeNewswire)
Aug-15-24 06:30AM	BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates (GlobeNewswire) -11.58%
06:30AM	BiomX Inc. Announces 1-for-10 Reverse Stock Split (GlobeNewswire)
Aug-08-24 07:00AM	BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024 (GlobeNewswire)
Jul-29-24 07:00AM	BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance (GlobeNewswire) -5.27%
Jul-10-24 06:30AM	BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock (GlobeNewswire) +8.20%
May-30-24 04:50PM	BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards (GlobeNewswire) +19.43%
07:00AM	BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024 (GlobeNewswire)
May-21-24 06:30AM	BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates (GlobeNewswire) +6.85%
May-15-24 07:00AM	BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024 (GlobeNewswire)
May-06-24 07:00AM	BiomX to Present at the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +6.28%
08:00AM	Loading…
Apr-23-24 08:00AM	BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024) (GlobeNewswire) +17.42%
Apr-18-24 08:00AM	BiomX Announces the Appointment of Susan Blum to its Board of Directors (GlobeNewswire) +5.61%
Apr-05-24 09:55AM	Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-04-24 07:49AM	BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure (GlobeNewswire) +8.57%
Apr-03-24 06:30AM	BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -8.90%
Mar-27-24 06:30AM	BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024 (GlobeNewswire) +6.07%
Mar-19-24 05:00AM	Telum Therapeutics appoints Dr. Subhendu Basu as CEO (PR Newswire)
Mar-18-24 06:30AM	BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing (GlobeNewswire)
Mar-06-24 07:30AM	BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing (GlobeNewswire) +197.66%
Jan-04-24 08:00AM	BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis (GlobeNewswire)
Nov-30-23 04:15PM	BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023 (GlobeNewswire) -13.67%
Nov-29-23 06:30AM	BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis (GlobeNewswire) -46.43%
Nov-14-23 06:30AM	BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-23 08:00AM	BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference (GlobeNewswire)
Oct-18-23 08:00AM	BiomX Announces the Appointment of Edward L. Williams to its Board of Directors (GlobeNewswire)
Oct-04-23 06:34AM	BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis (GlobeNewswire)
Sep-07-23 09:00AM	BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023 (GlobeNewswire)
Sep-06-23 04:05PM	BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-09-23 06:30AM	BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -9.29%
Aug-02-23 04:30PM	BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023 (GlobeNewswire)
Jun-08-23 05:00PM	NYSE American Initiates Delisting Proceedings for BiomX Warrants (GlobeNewswire)
May-31-23 03:00AM	BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Conference (ECFC) (GlobeNewswire) +13.56%
May-15-23 06:30AM	BiomX Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +7.17%
May-12-23 08:00AM	BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors (GlobeNewswire) +9.97%
May-08-23 06:30AM	BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023 (GlobeNewswire)
May-05-23 06:30AM	BiomX Announces Second Closing of $7.5 Million Private Placement (GlobeNewswire) +7.18%
Mar-29-23 06:30AM	BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-27-23 07:00AM	BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023 (GlobeNewswire) +7.00%
Feb-22-23 06:35AM	BiomX Announces $7.5 Million Private Placement (GlobeNewswire)
06:30AM	BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis (GlobeNewswire)
Nov-29-22 09:10AM	BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage (GlobeNewswire) +6.50%
Nov-09-22 06:30AM	BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-02-22 09:00AM	BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022 (GlobeNewswire)
Sep-11-22 07:22AM	BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference (Business Wire)
Aug-10-22 06:30AM	BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire) -6.41%
Aug-07-22 03:17AM	BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022 (Business Wire)
Aug-04-22 11:20AM	BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease (Business Wire) +6.18%
Jul-06-22 01:45AM	BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange (Business Wire) -5.37%
Jun-28-22 06:30AM	Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers (Business Wire)
Jun-27-22 06:30AM	BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis (Business Wire)
May-24-22 01:52AM	BiomX Announces Corporate Restructuring (Business Wire) +8.74%
May-20-22 08:00AM	BiomX Announces Publication in the Journal, Bioinformatics (Business Wire)
May-11-22 06:30AM	BiomX Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire) -6.09%
May-06-22 07:00AM	BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients (Business Wire)
May-05-22 08:00AM	BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022 (Business Wire)
Mar-30-22 06:30AM	BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (Business Wire) +14.38%
Mar-23-22 08:00AM	BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022 (Business Wire)
Feb-24-22 08:00AM	BiomX Presenting at Three Upcoming Investor Conferences (Business Wire)
Jan-04-22 07:00AM	BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation (Business Wire)
Nov-17-21 08:00AM	BiomX Presenting at Two Upcoming Conferences in November (GlobeNewswire)
Nov-15-21 06:00AM	BiomX Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-21 08:00AM	BiomX to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 15, 2021 (GlobeNewswire)
Oct-25-21 10:00AM	Down 28.1% in 4 Weeks, Here's Why BiomX Inc. (PHGE) Looks Ripe for a Turnaround (Zacks)
Oct-18-21 07:00AM	BiomX Reports Topline Results of Phase 2 Cosmetic Acne Study (GlobeNewswire) -12.35%
Oct-13-21 07:00AM	BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005 (GlobeNewswire) -5.15%
Sep-02-21 04:05PM	BiomX to Present at Upcoming September Investor Conferences (GlobeNewswire) -7.29% -5.15%
Aug-16-21 06:30AM	BiomX Reports Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire) -7.65%
Aug-12-21 08:00AM	BiomX to Host Second Quarter 2021 Financial Results Conference Call and Webcast on August 16, 2021 (GlobeNewswire)
Jul-26-21 08:13AM	BiomX Inc. Announces $15 Million Registered Direct Offering (GlobeNewswire) +9.45%
Jun-14-21 06:30AM	BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference and the International Conference on Phage Therapy and Bacteriophages (Business Wire)
Jun-09-21 06:30AM	BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference (Business Wire)
May-25-21 10:46AM	BiomX Reports Q1 Earnings; Shares Jump 6% (SmarterAnalyst)
May-24-21 06:30AM	BiomX Reports First Quarter 2021 Financial Results and Provides Business Updates (Business Wire)
06:15AM	BiomX Inc to Host Earnings Call (ACCESSWIRE)
May-18-21 08:00AM	BiomX To Host Key Opinion Leader Event on BX003 for the Treatment of Inflammatory Bowel Disease (GlobeNewswire)
06:30AM	BiomX to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 24, 2021 (Business Wire)
Apr-20-21 07:00AM	BiomX to Present at Upcoming April Investor Events (Business Wire)
Mar-31-21 06:30AM	BiomX Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update (Business Wire)
05:45AM	BiomX Inc to Host Earnings Call (ACCESSWIRE)
Mar-24-21 06:30AM	BiomX to Report Fourth Quarter and Full Year 2020 Financial Results on March 31, 2021 (Business Wire)

BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flynn James E	Director	Feb 27 '25	Option Exercise	0.93	706,498	657,467	1,247,054	Mar 03 07:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHGE

BiomX Inc

Upgrade your FINVIZ experience